Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014)

Palvella Therapeutics (PVLA) reported Non-Current Debt of $474.0 for Q3 2014, little changed quarter-over-quarter from $474.0 in Q2 2014.

Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014) Analysis & Trends

Palvella Therapeutics (PVLA) has 2 years of Non-Current Debt data on file, last reported at $474.0 in Q3 2014.

Non-Current Debt for Q3 2014 came in at $474.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2014 was $474.0 (changed N/A YoY), and the FY2014 annual result was $474.0, changed N/A from the prior year.
Non-Current Debt steadied at $474.0 in Q3 2014 per PVLA's latest filing, from $474.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $1.4 million in Q4 2013 and troughed at $474.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Palvella Therapeutics	1.49 Bn	1.23 Bn	-	-

Download Data